Respiratory Syncytial Virus; Anti-viral immunity in humans and macaques.
(Respiratoir syncytieel virus: anti-virale immuniteit in mensen en makaken)
2003-12-10
Doctoral Thesis
| Related Files |
|---|
|
(Waal Dissertation.pdf, 7.9MB) |
|
(03.pdf, 3.0MB) |
|
(04.pdf, 2.2MB) |
|
(01.pdf, 1.1MB) |
|
(02.pdf, 1.0MB) |
|
(20.pdf, 0.9MB) |
|
(22.pdf, 0.2MB) |
|
(21.pdf, 0.1MB) |
|
(003.pdf, 0.1MB) |
|
(30.pdf, 0.1MB) |
|
(00.pdf, 0.1MB) |
|
(001.pdf, 0.1MB) |
|
(004.pdf, 0.1MB) |
|
(31.pdf, 0.1MB) |
The results presented in this thesis show that hRSV infection in humans results in a multifaceted immune response, which cannot be described as purely Th1- or Th2-like. However, the observed higher level of IL-13 producing hRSV-specific T cells in infants hospitalized with severe hRSV bronchiolitis could provide a clue for an immunopathological mechanism of natural hRSV-mediated severe disease. Another hRSV-specific immunological factor potentially involved in the pathogenesis of severe hRSV disease could be the frequency and/or phenotype like those of HLADP4-restricted T cell responses directed to the conserved region of the RSV G protein. The BBG2Na- and rMVA-F/G-based vaccination strategies evaluated in infant macaques resulted in low VN and cellular immune responses and no detectable protection. A combination of both approaches in a prime-boost regime could possibly increase vaccine immunogenicity, but in this case the immunopathological safety would again have to be evaluated in different animal models.
EC 5th FWP (grant no. QLK2-1999-01044)
Netherlands Organisation for Health Science (grant no. 940-35-025)
Netherlands
Asthma Foundation (grant no. NAF 93.96.1)
Sophia Foundation for Medical Research
(grant no. 214)
Osterhaus, Prof. Dr. A.D.M.E. (promotor)
- virus
- response
- infection
- syncytial
- protein
- infant
- syncytial virus
- animal
- vaccine
- study
- hrsv-specific
- epitope
- chapter
- vaccination
- t cells
- syncytial virus infection
- figure
- disease
- hrsv infection
- class